1. Home
  2. MDWD vs AFCG Comparison

MDWD vs AFCG Comparison

Compare MDWD & AFCG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • AFCG
  • Stock Information
  • Founded
  • MDWD 2000
  • AFCG 2020
  • Country
  • MDWD Israel
  • AFCG United States
  • Employees
  • MDWD N/A
  • AFCG N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • AFCG Real Estate Investment Trusts
  • Sector
  • MDWD Health Care
  • AFCG Real Estate
  • Exchange
  • MDWD Nasdaq
  • AFCG Nasdaq
  • Market Cap
  • MDWD 184.8M
  • AFCG 189.9M
  • IPO Year
  • MDWD 2014
  • AFCG 2021
  • Fundamental
  • Price
  • MDWD $18.23
  • AFCG $6.76
  • Analyst Decision
  • MDWD Strong Buy
  • AFCG Buy
  • Analyst Count
  • MDWD 2
  • AFCG 6
  • Target Price
  • MDWD $32.00
  • AFCG $12.00
  • AVG Volume (30 Days)
  • MDWD 65.1K
  • AFCG 228.4K
  • Earning Date
  • MDWD 03-19-2025
  • AFCG 03-13-2025
  • Dividend Yield
  • MDWD N/A
  • AFCG 23.35%
  • EPS Growth
  • MDWD N/A
  • AFCG N/A
  • EPS
  • MDWD N/A
  • AFCG 0.78
  • Revenue
  • MDWD $19,720,000.00
  • AFCG $41,494,025.00
  • Revenue This Year
  • MDWD $10.15
  • AFCG N/A
  • Revenue Next Year
  • MDWD $25.62
  • AFCG N/A
  • P/E Ratio
  • MDWD N/A
  • AFCG $8.63
  • Revenue Growth
  • MDWD N/A
  • AFCG N/A
  • 52 Week Low
  • MDWD $12.78
  • AFCG $6.52
  • 52 Week High
  • MDWD $24.00
  • AFCG $10.88
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 55.16
  • AFCG 22.65
  • Support Level
  • MDWD $16.00
  • AFCG $8.33
  • Resistance Level
  • MDWD $18.29
  • AFCG $8.55
  • Average True Range (ATR)
  • MDWD 1.00
  • AFCG 0.32
  • MACD
  • MDWD 0.16
  • AFCG -0.10
  • Stochastic Oscillator
  • MDWD 75.24
  • AFCG 11.85

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About AFCG AFC Gamma Inc.

Advanced Flower Capital Inc is a commercial mortgage REIT that provides institutional loans to state-law-compliant cannabis operators in the U.S. Through the management team's deep network and significant credit and cannabis expertise, AFC originates, structures and underwrites loans ranging from $10 million to over $100 million, typically secured by quality real estate assets, license value and cash flows.

Share on Social Networks: